Literature DB >> 18024407

D-HPLC analysis of the entire FLT3 gene in MLL rearranged and hyperdiploid acute lymphoblastic leukemia.

Ronald W Stam1, Monique L den Boer, Pauline Schneider, Marrit Meier, H Berna Beverloo, Rob Pieters.   

Abstract

MLL rearranged and hyperdiploid acute lymphoblastic leukemia (ALL) are characterized by high-level FLT3 expression and constitutive FLT3 activation. As known activating FLT3 mutations are often absent in these patients, we screened the entire FLT3 coding sequence in MLL rearranged and hyperdiploid ALL cases for yet unidentified additional genetic alterations using denaturing D-HPLC. Both in MLL rearranged and hyperdiploid ALL we found that a small minority of samples, 7% and 10% respectively, carried genetic alterations. Although some of these alterations may induce FLT3 activation, the majority of these patients carry wild-type FLT3 genes.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18024407     DOI: 10.3324/haematol.11220

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  9 in total

1.  Backtracking RAS mutations in high hyperdiploid childhood acute lymphoblastic leukemia.

Authors:  Joseph L Wiemels; Michelle Kang; Jeffrey S Chang; Lily Zheng; Carina Kouyoumji; Luoping Zhang; Martyn T Smith; Ghislaine Scelo; Catherine Metayer; Patricia Buffler; John K Wiencke
Journal:  Blood Cells Mol Dis       Date:  2010-08-05       Impact factor: 3.039

Review 2.  Revisiting the biology of infant t(4;11)/MLL-AF4+ B-cell acute lymphoblastic leukemia.

Authors:  Alejandra Sanjuan-Pla; Clara Bueno; Cristina Prieto; Pamela Acha; Ronald W Stam; Rolf Marschalek; Pablo Menéndez
Journal:  Blood       Date:  2015-10-13       Impact factor: 22.113

Review 3.  Hyperdiploidy: the longest known, most prevalent, and most enigmatic form of acute lymphoblastic leukemia in children.

Authors:  Oskar A Haas; Arndt Borkhardt
Journal:  Leukemia       Date:  2022-10-20       Impact factor: 12.883

4.  The clinical characteristics, therapy and outcome of 85 adults with acute lymphoblastic leukemia and t(4;11)(q21;q23)/MLL-AFF1 prospectively treated in the UKALLXII/ECOG2993 trial.

Authors:  David I Marks; Anthony V Moorman; Lucy Chilton; Elisabeth Paietta; Amir Enshaie; Gordon DeWald; Christine J Harrison; Adele K Fielding; Letizia Foroni; Anthony H Goldstone; Mark R Litzow; Selina M Luger; Andrew K McMillan; Janis Racevskis; Jacob M Rowe; Martin S Tallman; Peter Wiernik; Hillard M Lazarus
Journal:  Haematologica       Date:  2013-01-24       Impact factor: 9.941

5.  Ligand-independent FLT3 activation does not cooperate with MLL-AF4 to immortalize/transform cord blood CD34+ cells.

Authors:  R Montes; V Ayllón; C Prieto; A Bursen; C Prelle; D Romero-Moya; P J Real; O Navarro-Montero; C Chillón; R Marschalek; C Bueno; P Menendez
Journal:  Leukemia       Date:  2013-11-18       Impact factor: 11.528

6.  FLT3 is implicated in cytarabine transport by human equilibrative nucleoside transporter 1 in pediatric acute leukemia.

Authors:  Albert Català; Marçal Pastor-Anglada; Liska Caviedes-Cárdenas; Roberta Malatesta; Susana Rives; Nerea Vega-García; Mireia Camós; Paula Fernández-Calotti
Journal:  Oncotarget       Date:  2016-08-02

7.  Point Mutations in the FLT3-ITD Region Are Rare but Recurrent Alterations in Adult AML and Associated With Concomitant KMT2A-PTD.

Authors:  Sebastian Stasik; Michael Kramer; Sven Zukunft; Christoph Röllig; Claudia D Baldus; Uwe Platzbecker; Hubert Serve; Carsten Müller-Tidow; Kerstin Schäfer-Eckart; Martin Kaufmann; Stefan Krause; Tim Sauer; Mathias Hänel; Andreas Neubauer; Gerhard Ehninger; Martin Bornhäuser; Johannes Schetelig; Jan M Middeke; Christian Thiede
Journal:  Front Oncol       Date:  2022-03-21       Impact factor: 6.244

8.  The evolution of clinical trials for infant acute lymphoblastic leukemia.

Authors:  R S Kotecha; N G Gottardo; U R Kees; C H Cole
Journal:  Blood Cancer J       Date:  2014-04-11       Impact factor: 11.037

Review 9.  MLL-Rearranged Acute Leukemia with t(4;11)(q21;q23)-Current Treatment Options. Is There a Role for CAR-T Cell Therapy?

Authors:  Oliver Britten; Denise Ragusa; Sabrina Tosi; Yasser Mostafa Kamel
Journal:  Cells       Date:  2019-10-29       Impact factor: 6.600

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.